Abstract:Abstract Background Colorectal cancer is the second leading cause of cancer death in Canada. A major risk factor for the development of colorectal cancer is chronic inflammation leading to colitis-associated cancer (CAC). We previously described a CAC mouse model in which tumors arise from DCLK1+ tuft cells following loss of the tumor suppressor adenomatous polyposis coli (APC) and induction of colitis. Interestingly, both colitis and CAC display epigenetic changes that modulate gene expression. However, the impact of DNA methylation changes on colonic tumorigenesis is not known. Thus, we hypothesize that inhibition of DNA methylation in DCLK1+ tuft cells reduces colonic tumorigenesis. Purpose In this study, we aim to investigate the role of DNA methylation in CAC by inhibiting DNA methylation using genetic and pharmacologic means. Method Using a publicly available dataset (GSE75214) of gene expression data analyzed by microarray from colonic biopsies of patients with ulcerative colitis and Crohn’s Disease with active disease, we examined the expression of DNA methyltransferases (DNMTs). Expression of DNMTs in mice with colitis was additionally examined by RT-qPCR and global DNA methylation levels measured by 5-mC ELISA. In separate experiments, Dclk1-CreERT2/Apcf/f mice were crossed to DNMT1f/f mice to knock-out the DNA methyltransferase DNMT1 in DCLK1+ tuft cells. Dclk1/Apcf/f and Dclk1/Apcf/f/DNMT1f/f mice were then administered three doses of tamoxifen followed by 2.5% dextran sodium sulfate (DSS) for five days to induce colitis. Fourteen weeks later, we assessed colonic tumor number and size. In a separate cohort of Dclk1/Apcf/f mice, we induced colitis and treated the mice with six doses of the DNA de-methylating drug 5-AZA-2’-deoxycytidine (5-AZA) or vehicle, and assessed colonic tumor number. To examine DNA methylation changes, we then treated WT mice with 5-AZA and DSS and isolated intestinal epithelial cells. From the intestinal epithelial cell, we isolated DNA and ran the Infinium MouseMethylation BeadChip Array. Result(s) Patients with IBD were found to have increased expression of DNMT1 compared to healthy controls. Mice treated with DSS similarly had increased DNMT1 expression, as well as, global methylation levels compared to controls. Deletion of DNMT1 in DCLK1+ cells significantly inhibited the number and size of colonic tumors. Treatment of mice with 5-AZA decreased global and gene specific DNA methylation levels, and significantly reduced both the number of mice with tumors, and the average colonic tumor number and size per mouse. Conclusion(s) Our findings demonstrate that colitis in both patients and mice is associated with DNA methylation. Furthermore, DNA hypomethylation by 5-AZA treatment or loss of DNMT1 reduces CAC formation suggesting that altered DNA methylation plays a critical role in colonic tumorigenesis. Disclosure of Interest None Declared

Inhibition of DNMT Suppresses the Stemness of Colorectal Cancer Cells Through Down-Regulating Wnt Signaling Pathway.

Inhibition of the Extracellular Signal-Regulated Kinase/mitogen-Activated Protein Kinase Pathway Decreases DNA Methylation in Colon Cancer Cells.

Inhibition of DNA Methyltransferase Induces G2 Cell Cycle Arrest and Apoptosis in Human Colorectal Cancer Cells Via Inhibition of JAK2/STAT3/STAT5 Signalling

Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell-like Phenotypes through Repressing Wnt/beta-catenin Signaling

The Demethylating Agent 5-Aza-2'-deoxycytidine Prevents Tumorigenesis in a Mouse Model of Colorectal Cancer

Data from Downregulation of DNMT3A by Mir-708-5p Inhibits Lung Cancer Stem Cell–like Phenotypes Through Repressing Wnt/β-catenin Signaling

Targeted DNA Demethylation of the ZNF334 Promoter Inhibits Colorectal Cancer Growth

A35 DNA HYPOMETHYLATION INHIBITS TUFT CELL-DERIVED COLITIS-ASSOCIATED CANCER

A27 DNA HYPOMETHYLATION INDUCED BY 5-AZA-CDR OR LOSS OF DNMT1 INHIBITS COLITIS-ASSOCIATED COLORECTAL CANCER

Microrna-342 Inhibits Colorectal Cancer Cell Proliferation and Invasion by Directly Targeting Dna Methyltransferase 1

Inhibitor Of Dna Binding1 (Id1) Mediates Stemness Of Colorectal Cancer Cells Through The Id1-C-Myc-Plac8 Axis Via The Wnt/Beta-Catenin And Shh Signaling Pathways

The Stem Cell Gene Abcb5 Regulates Dna Methylation in Colorectal Cancer

DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation

Hypermethylation of DMTN Promotes the Metastasis of Colorectal Cancer Cells by Regulating the Actin Cytoskeleton Through Rac1 Signaling Activation.

Temporal DNA Methylation Pattern and Targeted Therapy in Colitis-Associated Cancer

Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer

Epigenetic Modification Regulates Both Expression of Tumor-Associated Genes and Cell Cycle Progressing in Human Colon Cancer Cell Lines: Colo-320 and SW1116.

Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC

Methylated+58cpg Site Decreases Dcn Mrna Expression And Enhances Tgf-Beta/Smad Signaling In Nsclc Cells With High Metastatic Potential

Enhanced binding of β-catenin and β-TrCP mediates LMPt's anti-CSCs activity in colorectal cancer

Proteasome inhibition induces DNA methylation alteration by attenuating the synthesis of DNA methyltransferase 1 and 3B in colorectal cancer